For one participant, the change announced itself as silence.

Before they started a GLP-1 medication, food was everywhere. “My whole world was around food,” they told researchers. “If I’m bored, food; sad, food; upset, food.”

Then the medication quieted something they had carried for years: the constant pull toward eating, even when what they felt was emotion, and not hunger.

That quieting of “food noise,” the relentless inner stream of cravings, urges and preoccupations around eating, sits at the heart of a new study from researchers at the Stanford Center for Digital Health, published in JAMA Network Open. The study was led by first author Isabella de Vere Hunt, MD, with co-authors Mariana Ramirez-Posada, Christopher Sam Babu, Cati Brown-Johnson, PhD, Eleni Linos, MD, MPH, DrPH, and Fatima Rodriguez, MD, MPH. 

“I found these patients’ accounts really impactful in helping me understand how the medication was affecting patients’ relationship with food and how extreme the reduction in ‘food noise’ was for some people,” she said.

That shift helps explain the extraordinary enthusiasm surrounding GLP-1 medications. For some patients, weight loss was only part of the story. The larger transformation was a sense of control.

“The eating isn’t telling me what to do,” as one participant shared.

Not a Magic Bullet

The study also unsettles the popular image of GLP-1 drugs as effortless cures.

Participants pushed back, again and again, on the idea that the medications worked like magic. Most described them instead as tools, something that opened room for change rather than delivering it on its own.

“I have to shop differently,” one participant said. “I have to plan differently. And then I have to cook and eat differently.”

For others, the medication supplied momentum. As the weight came off, some felt more motivated to exercise, more at ease being seen in public, more able to build routines that had long felt out of reach.

That distinction is important, de Vere Hunt stresses, especially as policymakers and health systems debate who should be able to access these medications.

“Medications are not a standalone solution to obesity,” she said. “Participants consistently described GLP-1s as a tool that enabled healthier behaviours rather than replacing them.”

Expanding access to effective medications, she added, should go hand in hand with “sustained investment in behavioural support and obesity prevention” if the goal is meaningful, long-term improvement in metabolic health.

The Trade-Offs

No benefit came completely free.

Some participants reported mild nausea. Others endured severe gastrointestinal symptoms, including vomiting, diarrhea, cramping and abdominal pain. Several stopped the medication entirely once the side effects became intolerable.

What struck the researchers was not just the range of those effects, but how much some patients were willing to absorb because the benefits felt so significant.

“I was willing to live with it because the results were so immediate and helpful,” one participant said. “I was at the end of my rope with regard to my weight. And I was like, ‘I don’t want to die overweight and unhappy.’ And so I just decided to weather it.”

The interviews also suggested many patients were not necessarily getting the kind of detailed, ongoing guidance that could help them manage or expect those symptoms. As one participant noted, when they began experiencing gastrointestinal upset, they “had no idea it was from the drug.”  

For de Vere Hunt, that kind of support should not be optional.

“Don’t underestimate the impact that an extra few minutes spent setting expectations, discussing likely side effects, and exploring patients’ concerns could have on a patient’s whole treatment journey and weight loss outcomes,” de Vere Hunt said. “Those conversations can improve confidence, help patients navigate challenges, and ultimately make the difference in terms of treatment adherence and success.”

“GLP-1 RAs should always be embedded within ongoing, holistic weight-management care,” she said. That means clear counseling about what to expect, likely side effects, coping strategies, long-term treatment plans, nutrition, physical activity, and what to do if problems arise.

“GLP-1s can be a very powerful tool,” she said, “but they’re never the entire solution.”

Who Gets Access?

For some participants, the hardest part was not taking the medication. It was getting access to it.

They described insurance denials, pharmacy shortages, and punishing out-of-pocket costs. One patient stopped treatment not because it had failed, but because tuition came first.

“I took it from January to April, and I lost 70 pounds,” the participant said. “And then I stopped only because I had to pay for my tuition, and it ain’t cheap.”

Another recalled the work of staying on treatment during shortages, calling pharmacy after pharmacy in search of an available dose.

Access to GLP-1 therapy, the study suggests, often hinges on far more than a prescription. It can demand time, persistence, health literacy, money, and the confidence to advocate for oneself.

“I had to actually advocate for myself to get it because it’s very, very, very expensive,” one participant said. “Can I stress how expensive this drug is, or these GLP-1s? It was hard.”

In that way, the medications may be deepening an uncomfortable divide between those who can navigate the health care system and those who cannot.

De Vere Hunt said the study raises questions not only about affordability, but about the rules used to determine who qualifies.

“We should re-examine eligibility frameworks for GLP-1 therapies,” she said. “In our study, criteria anchored to diabetes-related thresholds appeared to reinforce the perception that obesity alone is not a legitimate reason for treatment, potentially contributing to ongoing stigma around pharmacological treatment for weight management.”

The Stigma Around Help

That question of who qualifies for treatment also shaped another major theme in the interviews: stigma.

Many participants felt judged for using medication to lose weight. Some had been accused of taking “the easy way out.” 

“I think that there is kind of a stigma that it’s a cop-out,” one participant said, “that you’re just taking the easy way out rather than doing it with diet and exercise like you should.”

Reflecting on the findings, de Vere Hunt shares, “I expected perceived stigma to be present for people taking GLP-1 RA medications, but I was surprised by how strongly it still emerged in interviews.”

A particularly important finding, she added, was that many participants felt society viewed GLP-1 use differently depending on the reason: diabetes treatment was seen as legitimate, while obesity treatment was often framed as “cheating.”

“Biologically this doesn’t make much sense,” de Vere Hunt said, “as obesity is also a chronic disease involving dysregulated hormonal and metabolic pathways with serious long-term health implications.”

Yet eligibility criteria, she said, can reinforce the misconception that people do not need medical support to treat obesity alone.

“I really hope stigma will diminish over time as public understanding shifts to accept that obesity is a chronic disease and not a lifestyle choice,” she said.

More Human Than Miracle

For many patients, the therapy worked as a facilitator: a tool that opened just enough distance between impulse and action for healthier choices to become possible. It did not erase the need for effort. It changed what patients could do with that effort.

The study also points to what patients may need beyond the prescription itself: clearer counseling about side effects, steadier clinical support, behavioral strategies, peer connection, and policies that make access less dependent on wealth, luck, or sheer persistence.

As policymakers debate coverage, clinicians weigh long-term strategies, and society argues over who deserves access, the voices in this study are a reminder that the story of GLP-1 medications was never only about weight loss as much as it is about agency.

For some patients, the most meaningful outcome was not a smaller number on the scale. It was discovering what life could feel like when food was no longer in charge.